I

InflaRx NV
D

IFRX

2.09000
USD
-0.01
(-0.48%)
Market Closed
Volume
3,192
EPS
-1
Div Yield
-
P/E
-2
Market Cap
123,066,038
Related Instruments
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: InflaRx NV

Sector: Healthcare
Industry: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.